BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Small cell lung cancer clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for small cell lung cancer: 1166 (384 sponsors; 120 newly posted in the last 180 days, 57 stopped in the last 180 days; 39 new-entrant sponsors). Momentum score 15.5, rank 41 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 7, Phase 1 254, Phase 2 397, Phase 3 250, Phase 4 6, N/A 86.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| AstraZeneca AZN | 84 | P3 31, P4 1, P2 23, NA 23, P1 6 | 5 | 8 |
| Merck Sharp & Dohme LLC MRK | 33 | P3 20, NA 1, P2 12 | 1 | 4 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 27 | P2 11, P3 10, P1 6 | 5 | 7 |
| Bristol-Myers Squibb BMY | 25 | P3 9, P2 9, NA 3, P1 4 | 4 | 2 |
| Amgen AMGN | 22 | P3 9, P1 8, P2 5 | 1 | 3 |
| Akeso | 14 | P3 7, P2 7 | 2 | 2 |
| Hoffmann-La Roche | 10 | P3 7, NA 1, P2 2 | 0 | 1 |
| Daiichi Sankyo | 17 | P2 7, P3 6, P1 3, NA 1 | 2 | 1 |
| Eli Lilly and Company LLY | 17 | P1 7, P2 3, P3 6, P4 1 | 1 | 2 |
| AbbVie ABBV | 16 | P2 5, P3 6, P1 5 | 3 | 0 |
| Qilu Pharmaceutical Co., Ltd. | 8 | P3 6, P2 1, P1 1 | 1 | 3 |
| Pfizer PFE | 25 | P3 5, P1 8, P2 6, P4 3, NA 3 | 3 | 2 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | 15 | P3 5, P1 9, P2 1 | 3 | 3 |
| Shanghai Henlius Biotech | 14 | P2 6, P1 3, P3 5 | 1 | 2 |
| Shanghai JMT-Bio Inc. | 7 | P2 2, P3 5 | 0 | 1 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | 12 | P2 8, P3 4 | 3 | 2 |
| Allist Pharmaceuticals, Inc. | 8 | P3 4, P2 3, P1 1 | 0 | 3 |
| GlaxoSmithKline | 7 | P2 2, P3 4, P1 1 | 2 | 0 |
| Janssen Research & Development, LLC | 11 | NA 1, P2 5, P3 3, P1 2 | 0 | 5 |
| Gilead Sciences GILD | 5 | P3 3, P2 2 | 0 | 0 |
| Mirati Therapeutics Inc. | 5 | P2 2, P3 3 | 0 | 0 |
| Changchun GeneScience Pharmaceutical Co., Ltd. | 3 | P3 3 | 0 | 1 |
| Summit Therapeutics SMMT | 3 | P3 3 | 0 | 0 |
| Boehringer Ingelheim | 13 | NA 2, P1 6, P2 3, P3 2 | 3 | 5 |
| BioNTech SE BNTX | 8 | P2 5, P3 2, P1 1 | 0 | 0 |
Recently stopped trials
- NCT06980272 Shenyang Sunshine Pharmaceutical Co., LTD. - terminated: Sponsor decided SSGJ-707 in Advanced Non-Small Cell Lung Cancer
- NCT00434226 Genentech, Inc. - terminated: Based on data collected, the combination appeared to be poorly tolearated. A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Ce
- NCT06931626 Nerviano Medical Sciences - terminated: The decision about study closure has not been based on safety profile or clinical data of NMS-03305293 but due to a strategic decision drive Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
- NCT05462873 Novartis Pharmaceuticals - terminated: Business decision and not related to safety concerns A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
- NCT05194735 Alaunos Therapeutics - terminated: Sponsor halted enrollment on 14 Aug 2023 for business reasons after a Board review of funding needs and permanently discontinued TCR-T cell Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
- NCT05132075 Novartis Pharmaceuticals - terminated: Business reasons and not based on any safety concerns. Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-sm
- NCT07073183 CureVac - withdrawn: In accordance with 21 CFR 312.38, CureVac is herewith withdrawing IND No. 031346 for CV09070101 (referred to as CVHNLC) for the indication o Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)
- NCT07353957 Genmab - withdrawn: This study-level decision was based on the evolving treatment landscape and strategic portfolio considerations and is not related to any saf Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
- NCT06171789 Genmab - terminated: Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation PRO1107 in Patients With Advanced Solid Tumors
- NCT03371979 Immedica Pharma AB - terminated: Study enrollment was halted early based on ongoing data monitoring; no efficacy analyses were performed Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer
- NCT05378763 Spectrum Pharmaceuticals, Inc - suspended: The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA. A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 2
- NCT04868877 Merus B.V. - terminated: The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-r Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Soli
- NCT06364696 Astellas Pharma Inc - terminated: Company's strategic decision A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
- NCT05358249 Novartis Pharmaceuticals - terminated: Business reasons and not based on any safety concerns. Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
- NCT05879822 Incyte Corporation - terminated: This was a strategic business decision. There were no safety concerns contributing to this decision. A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P1/P2 | Monte Rosa Therapeutics, Inc GLUE | NCT05546268 Study of Oral MRT-2359 in Selected Cancer Patients | NSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC | active not recruiting | 174 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05924841 A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer | Small Cell Lung Cancer | recruiting | 100 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06437509 A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer | Extensive-stage Small-cell Lung Cancer | recruiting | 66 |
| 2026-12 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06500026 A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) | Small Cell Lung Cancer | active not recruiting | 722 |
| 2026-12 est. | P1/P2 | Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. | NCT07136285 Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC | SCLC, Extensive Stage | recruiting | 27 |
| 2026-12-15 est. | P1/P2 | PMV Pharmaceuticals, Inc PMVP | NCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung C | recruiting | 300 |
| 2026-12-18 est. | P2/P3 | Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | NCT07145333 Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms | SCLC | active not recruiting | 600 |
| 2026-12-31 est. | P1/P2 | OncoC4, Inc. | NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carc | active not recruiting | 733 |
| 2026-12-31 est. | P2 | Pfizer PFE | NCT04553133 PF-07104091 as a Single Agent and in Combination Therapy | Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer | active not recruiting | 157 |
| 2026-12-31 est. | P3 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT06961201 Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cache | Extensive-stage Small Cell Lung Cancer (ES-SCLC); The Pre-cachexia or Cachexia Patients Who Have Not | not yet recruiting | 94 |
| 2027-01 est. | P1/P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT07208773 A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | Advanced Solid Tumors; Non Small Cell Lung Cancer; Small Cell Lung Cancer | recruiting | 260 |
| 2027-02-14 est. | P1/P2 | Beijing Biotech | NCT07480213 Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC; SCLC, Extensive Stage | recruiting | 60 |
| 2027-02-14 est. | P1/P2 | Beijing Biotech | NCT07744256 Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC; Extensive-stage SCLC | recruiting | 60 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-18 est. | P2/P3 | Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | NCT01064466 Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms | Small Cell Lung Cancer | active not recruiting | 600 |
| 2026-10-22 est. | P2 | Shanghai Henlius Biotech | NCT06812260 A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC | SCLC, Extensive Stage | active not recruiting | 26 |
| 2026-09-28 | P1/P2 | Novartis Pharmaceuticals NVS | NCT05358249 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-S | terminated | 74 |
| 2026-09 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06469879 A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients | Small Cell Lung Cancer Limited Stage | unknown | 358 |
| 2026-09 est. | P1/P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT05978284 Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | Small Cell Lung Cancer; Neuroendocrine Carcinoma | recruiting | 54 |
| 2026-08-20 | P3 | Hansoh BioMedical R&D Company | NCT06498479 ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer | Small Cell Lung Cancer | completed | 461 |
| 2026-08 est. | P2 | Tasly Biopharmaceuticals Co., Ltd. | NCT06724263 A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | Recurrent Platinum-resistant Epithelial Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Cervic | not yet recruiting | 120 |
| 2026-08 est. | P1/P2 | Jacobio Pharmaceuticals Co., Ltd. | NCT05490472 JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | Solid Tumors; ER+ Breast Cancer; Triple Negative Breast Cancer, TNBC; ARID1A Gene Mutation; Small Ce | recruiting | 102 |
| 2026-06-30 est. | P3 | Shanghai Henlius Biotech | NCT05353257 A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cel | Limited-Stage Small Cell Lung Cancer | active not recruiting | 511 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "small cell lung cancer"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.